TerminatedPhase 3

Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo

Stopped: Sponsor decision, unrelated to safety

United States219 participantsStarted 2017-03-27

Plain-language summary

The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with adenoviral conjunctivitis.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Report presence of signs and/or symptoms of adenoviral conjunctivitis for lesser than or equal to (\<=) 4 days prior to Visit 1
✓. Bulbar conjunctival injection: a grade of \>= 1 (mild) on a 0-4 Bulbar Conjunctival Injection Scale.
✓. Watery conjunctival discharge: a grade of \>= 1 (mild) on a 0-3 Watery Conjunctival Discharge Scale

Exclusion criteria

✕. Have used an investigational product or device, or
✕. Have been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this Shire-sponsored study

What they're measuring

Number of Participants With Clinical Resolution Among Who Received SHP640 or Placebo on Day 6

Timeframe: Day 6

Trial details

NCT IDNCT02998541

SponsorShire

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-05-13

Results submitted2020-05-11

View on ClinicalTrials.gov More Adenoviral Conjunctivitis trials